Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1587802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Jorge Vasconez-Gonzalez und 10 weiteren Autor:innen. Beteiligte Einrichtung: One Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Vaccine Development, Viral Vaccines, HTLV-I Infections. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The human T-cell lymphotropic virus type 1 (HTLV-1) is a highly oncogenic retrovirus recognized as the causative agent of adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Among the key risk factors for ATLL development are high proviral load, reduced anti-Tax immune responses, and elevated levels of soluble interleukin-2 receptor. Unlike classical oncogenic viruses, HTLV-1 does not encode proto-oncogenes but instead drives cellular transformation through a combination of mechanisms, including viral gene dysregulation, chromatin remodeling, epigenetic reprogramming, persistent clonal expansion, immune evasion, and RNA-based modifications. Despite growing understanding of these molecular pathways, an effective prophylactic vaccine against HTLV-1 remains unavailable. However, several vaccine strategies including viral vector platforms, mRNA-based candidates, peptide vaccines, and dendritic cell-based approaches have shown promise in preclinical models. In this review, we provide a comprehensive synthesis of current knowledge on HTLV-1 oncogenesis, highlight the roles of viral proteins such as Tax and HBZ in immune evasion, and critically examine the state of vaccine development efforts aimed at controlling this neglected human retrovirus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- One Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
- Institute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador.
- Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador.
Zitieren
APA
Vasconez-Gonzalez, J., Suárez-Sangucho, I. A., Acosta-Muñoz, E., Miño, L. P. Y., Borja-Mendoza, D., Alexander-Castillo, J. A., Saa, J., Salazar-Calvopiña, N., Cárdenas, P., López-Cortés, A., & Ortiz-Prado, E. (2025). Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1587802
Vancouver
Vasconez-Gonzalez J, Suárez-Sangucho IA, Acosta-Muñoz E, Miño LPY, Borja-Mendoza D, Alexander-Castillo JA, et al. Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1587802
BibTeX
@article{VasconezGonzalez2025,
author = {Vasconez-Gonzalez, Jorge and Suárez-Sangucho, Isaac A and Acosta-Muñoz, Esteban and Miño, Luis Paz Y and Borja-Mendoza, Domenic and Alexander-Castillo, John Altamirano and Saa, Julia and Salazar-Calvopiña, Natasha and Cárdenas, Paúl and López-Cortés, Andrés and Ortiz-Prado, Esteban},
title = {Human T-cell leukemia virus type 1: oncogenic potential and vaccine development strategies},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1587802}
}
EUVIMED